Increases system flexibility when using multiple fluorescent and chromatic dyes

CompuCyte has expanded its iGeneration line of imaging cytometers to include four-laser versions of the iCyte, iCys and iColor systems.

With the option of four lasers chosen from a palette of 405, 488, 532, 561, 594 and 633 nanometers, these newly released analysers increase system flexibility when using multiple fluorescent and chromatic dyes.

Elena Holden, president and CEO of CompuCyte, said: “The instrument configuration with violet, blue, yellow, and red lasers is an instant winner with researchers. It allows them to take full advantage of the efficient members in the new ‘fruit’ series of fluorescent proteins, while at the same time providing full coverage of the chromatic dye absorption spectrum.

“The four-laser instruments offer researchers unmatched flexibility in the choice and combination of dyes, both fluorescent and chromatic. As a testament to the value of these new products, the first LSC upgrades were pre-ordered in March, in anticipation of their scheduled release in the fall of 2009. New instrument shipments began in November.”

Alexei Protopopov, director of Molecular Cytogenetics Laboratory and senior scientist at Dana-Farber Cancer Institute in Boston, Massachusetts, said: “The four-laser iCys is an important tool in our cancer research. The added laser gives us tremendous flexibility in dye selection and allows more stains to be used simultaneously, providing capabilities in our analyses of cells and tissues.

“We can now look at a number of indicators of tumor cell behavior simultaneously telomere erosion, centromere dynamics, and expression of specific proteins, for example. CompuCyte’s new four-laser instrument represents a major step forward in high-content cellular and tissue analysis, greatly facilitating our understanding of cancer.”

The company’s line of laser scanning cytometry instrumentation is applied to automated cellular and tissue analysis in life science research, drug safety, toxicology studies and clinical trials.